Eli Lilly announced that its investigational drug retatrutide met primary endpoints in the TRIUMPH-1 Phase 3 obesity trial.
2,339 adults with obesity or overweight without diabetes were evaluated over 80 weeks.
Participants on 12 mg lost an average of 70.3 pounds (28.3%). The 9 mg dose led to 64.4 pounds (25.9%), and 4 mg to 47.2 pounds (19.0%).
Placebo group lost 5.5 pounds (2.2%).
In those with baseline BMI ≥35, extending to 104 weeks, average loss was 85.0 pounds (30.3%).
45.3% on 12 mg achieved ≥30% weight loss at 80 weeks.
Cardiovascular risk factors improved.
Common adverse events included nausea, diarrhea, constipation, and vomiting.
Retatrutide remains investigational.
